daily oral glp-1 receptor agonist orforglipron for adults with obesity Orforglipron: The Non-Peptide Julio Rosenstock, MD Co-Authored an

Genistein enhances the secretion of glucagon-like peptide-1 (GLP-1) via downregulation of inflammatory responses

Most therapeutic peptides are administered as small subcutaneous injections, similar in size to an insulin needle, taken daily or several times per week depending on the protocol

Therefore, processes such as hypoxia and hyperoxia can disrupt oxidative balance and ultimately induce oxidative stress [12, 13], with ROS being one of the main participants [14]

Key gaps include: No large-scale randomised controlled trials in humans the evidence basis for clinical use is extrapolated from animal data and small pilot studies No long-term safety data effects beyond 1216 weeks are not well characterised Variable results in human sleep trials some early human studies showed modest or inconsistent effects on sleep architecture compared to animal data, suggesting the translation may not be linear No FDA approval DSIP is not approved for any therapeutic use in the United States Stability concerns DSIP degrades relatively quickly in circulation